Communiqués DiaSorin S.p.A.

Actions

DIA

IT0003492391

Equipement, fournitures et distribution médicale

Temps réel Borsa Italiana 14:05:20 04/09/2026			Varia. 5j.	Varia. 1 janv.
76,10 ^EUR	-0,86%		-0,68%	+10,90%

03/09	Italie - Les facteurs à suivre le 3 septembre	RE
01/09	Les données macroéconomiques tirent les bourses européennes vers le bas ; Eni progresse	AN

Communiqués

19/05	DiaSorin S p A : Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay	PU
04/05	DiaSorin S p A : Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President	PU
29/04	DiaSorin S p A : Shareholders' Meeting 2026	PU
20/03	DiaSorin S p A : 2026	PU
20/03	DiaSorin S p A : Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024	PU
19/03	DiaSorin S p A : signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform	PU
24/02	DiaSorin S p A : introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN	PU
03/02	DiaSorin S p A : submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver	PU
29/01	DiaSorin S p A : has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL	PU
26/01	DiaSorin S p A : signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel	PU
23/01	DiaSorin S p A : Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer.	PU
30/12	DiaSorin S p A : receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIAISON NES Molecular Diagnostics platform	PU
28/12	DiaSorin S p A : receives FDA 510(k) clearance and CLIA-waiver for its first assay, the 4-Plex Respiratory Panel, on the LIASON NES Molecular Diagnostics platform	PU
24/11	DiaSorin S p A : submits the LIAISON PLEX Gastrointestinal Flex Assay to the U.S. FDA for 510(k) Clearance	PU
18/11	DiaSorin S p A : , in partnership with QIAGEN, unveils the next generation of the LIAISON QuantiFERON-TB Gold Plus II assay to deliver significant testing productivity and faster results in all Countries accepting the CE mark	PU
31/10/25	DiaSorin S p A : receives 510(k) clearance for Simplexa COVID-19, Flu A/B & RSV Direct kit on the LIAISON MDX from the U.S. Food and Drug Administration	PU
22/10/25	DiaSorin S p A : signs a supplier agreement with Quest Diagnostics for the innovative molecular multiplexing platform, LIAISON PLEX	PU
19/09/25	DiaSorin S p A : launches LIAISON® TSH-R Ab, an immunodiagnostic assay to improve Graves’ Disease diagnosis, in all countries accepting CE mark	PU
08/09/25	DiaSorin S p A : New evidence on MeMed BV's role in supporting emergency medicine clinical decisions unveiled at ACEP 2025	PU
31/07/25	DiaSorin S p A : Revenue Growth and Margin Expansion in H1 2025. FY 2025 Guidance Confirmed	PU
02/07/25	DiaSorin S p A : submits the LIAISON NES® Point-of-Care molecular diagnostics system and 4-plex Respiratory Panel to the FDA for 510(k) Clearance and CLIA Waiver	PU
07/06/25	DiaSorin S p A : announces 510(k) clearance for LIAISON PLEX® Gram-Positive Blood Culture Assay, to complete the Blood Culture portfolio on LIAISON PLEX®	PU
18/04/25	DiaSorin S p A : receives 510(k) clearance for its second multiplex molecular panel for diagnosing bloodstream infections on LIAISON PLEX®	PU
04/04/25	DiaSorin S p A : Notice pursuant to art. 144-octied, para. 2 of CONSOB regulation No. 1971/1999	PU
18/03/25	DiaSorin S p A : launches the Simplexa™ C. auris direct assay on the LIAISON® MDX instrument in all countries accepting the CE Mark	PU